Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IPA logo IPA
Upturn stock ratingUpturn stock rating
IPA logo

Immunoprecise Antibodies Ltd (IPA)

Upturn stock ratingUpturn stock rating
$2.37
Last Close (24-hour delay)
Profit since last BUY415.22%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/29/2025: IPA (4-star) is a SELL. SELL since 1 days. Profits (415.22%). Updated daily EoD!

Upturn Star Rating

rating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Number of Analysts

rating

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $0.27
Current$2.37
52w High $3.25

Analysis of Past Performance

Type Stock
Historic Profit 319.81%
Avg. Invested days 43
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/29/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 114.92M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 2
Beta 0.55
52 Weeks Range 0.27 - 3.25
Updated Date 08/30/2025
52 Weeks Range 0.27 - 3.25
Updated Date 08/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.66

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -123.3%
Operating Margin (TTM) -21.11%

Management Effectiveness

Return on Assets (TTM) -14.81%
Return on Equity (TTM) -101.96%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 111371814
Price to Sales(TTM) 4.69
Enterprise Value 111371814
Price to Sales(TTM) 4.69
Enterprise Value to Revenue 6.26
Enterprise Value to EBITDA -4.68
Shares Outstanding 46154100
Shares Floating 41946709
Shares Outstanding 46154100
Shares Floating 41946709
Percent Insiders 9.07
Percent Institutions 8.67

ai summary icon Upturn AI SWOT

Immunoprecise Antibodies Ltd

stock logo

Company Overview

overview logo History and Background

Immunoprecise Antibodies Ltd. is a biopharmaceutical company focused on therapeutic antibody discovery and development. Founded in 1989, it has evolved from a contract research organization (CRO) to an integrated discovery platform offering services and technologies across the antibody discovery value chain.

business area logo Core Business Areas

  • Therapeutic Antibody Discovery: Offers a range of services for the discovery of monoclonal and bispecific antibodies, including hybridoma technology, B cell screening, and phage display. Services extend from antigen design to antibody sequencing and characterization.
  • Recombinant Antibody Production: Provides recombinant antibody production services, including antibody engineering, optimization, and scale-up production.
  • Contract Research Services: Offers in vitro and in vivo research services for preclinical antibody development, including preclinical testing.

leadership logo Leadership and Structure

Dr. Jennifer Bath serves as President and CEO. The company has a board of directors and operates with distinct functional teams focused on research, operations, and commercial activities.

Top Products and Market Share

overview logo Key Offerings

  • Antibody Discovery Services: Comprehensive antibody discovery platform offering various technologies. Market share data is not precisely defined due to the fragmented nature of the CRO market, but the company competes with larger CROs and specialized antibody discovery firms. Competitors: Charles River Laboratories, WuXi AppTec, GenScript Biotech.
  • Custom Antibody Production: Custom antibody production from milligram to gram scale. Competes with other CROs, typically serving smaller pharmaceutical and biotechnology firms. Competitors: Thermo Fisher Scientific, Abcam.
  • Preclinical Research Services: Offers preclinical in vivo and in vitro research services. Competes with other preclinical CROs. Competitors: Covance, Charles River Laboratories.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry, and especially the antibody therapeutics segment, is experiencing substantial growth driven by advances in immunotherapy, targeted therapies, and diagnostics. The CRO market is also expanding, driven by the increasing R&D spending in the pharmaceutical sector and the need for specialized expertise.

Positioning

Immunoprecise Antibodies Ltd. positions itself as a full-service antibody discovery and development company, providing integrated solutions from target identification to preclinical development. Its competitive advantages include its diverse technology platform and its focus on complex targets.

Total Addressable Market (TAM)

The global antibody therapeutics market is estimated to reach hundreds of billions of dollars. The global CRO market is in the tens of billions. Immunoprecise Antibodies Ltd. targets a segment of this market, focusing on early-stage antibody discovery and preclinical services.

Upturn SWOT Analysis

Strengths

  • Comprehensive antibody discovery platform
  • Expertise in complex targets
  • Integrated service offerings
  • Experienced leadership team

Weaknesses

  • Relatively small size compared to major CROs
  • Limited marketing resources
  • Dependence on research funding trends
  • Limited late-stage clinical development capabilities

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships with larger pharmaceutical companies
  • Increased demand for antibody therapeutics
  • Leveraging AI and machine learning for antibody discovery

Threats

  • Competition from larger CROs
  • Patent disputes
  • Changes in regulatory landscape
  • Economic downturn affecting research funding

Competitors and Market Share

competitor logo Key Competitors

  • Charles River Laboratories (CRL)
  • WuXi AppTec (WXUSF)
  • Thermo Fisher Scientific (TMO)

Competitive Landscape

Immunoprecise Antibodies Ltd. is significantly smaller than its main competitors, such as Charles River Laboratories and WuXi AppTec. It competes by offering specialized expertise and integrated solutions, targeting niche markets and smaller pharmaceutical companies.

Major Acquisitions

BioStrand BV

  • Year: 2022
  • Acquisition Price (USD millions): 14.5
  • Strategic Rationale: Accelerated discovery of novel antibody therapeutics, expands IP portfolio, increases competitiveness.

Growth Trajectory and Initiatives

Historical Growth: Historical growth depends on financial data which is not available.

Future Projections: Future projections depend on analyst estimates, which can vary based on market conditions and company performance. Analyst estimates depend on financial data which is not available.

Recent Initiatives: Expanding its technology platform through acquisitions and strategic alliances and focusing on high-growth areas like multi-specific antibody therapies.

Summary

Immunoprecise Antibodies Ltd. is a biopharmaceutical company that specializes in antibody discovery and development. It offers a comprehensive service portfolio and has made strategic acquisitions to expand its capabilities. While smaller than its major competitors, it serves the needs of small to medium pharmaceutical companies. Moving forward, it should focus on expanding sales, marketing, and production efficiency.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • Industry Reports
  • Analyst Reports
  • Public Filings

Disclaimers:

This analysis is based on publicly available information and represents a general overview of Immunoprecise Antibodies Ltd. Financial data is estimated or based on industry averages due to availability constraints.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Immunoprecise Antibodies Ltd

Exchange NASDAQ
Headquaters Austin, TX, United States
IPO Launch date 2017-01-03
CEO, President & Non-Independent Director Dr. Jennifer Lynne Bath Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 81
Full time employees 81

ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas.